Álvaro Juárez Soto, MD, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer evaluated in the phase 3 TITAN trial.
Álvaro Juárez Soto, MD, chief, Urology Service, Hospital Universitario de Jerez, Cádiz, Spain, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated in the phase 3 TITAN trial (NCT02489318).
Findings from the interim analysis of the TITAN trial demonstrated improved overall survival and radiographic progression-free survival with the addition of apalutamide (Erleada) to androgen deprivation therapy (ADT) vs placebo plus ADT in men with mHSPC.
Since geographical differences in disease presentation and management could exist in patients with mHSPC, a post-hoc analysis of the TITAN study evaluated the Latin American subgroup of patients treated on the trial, Juárez Soto says.
The results of the post-hoc analysis, which were presented in a virtual poster during week 2 of the 2021 AACR Annual Meeting, confirmed that the addition of apalutamide to ADT was beneficial for Latin American patients vs placebo plus ADT, Juárez Soto explains. Moreover, since no differences between this subgroup and the overall population were observed, apalutamide should be considered for a broad patient population, Juárez Soto concludes.